Auris Medical Holding (EARS) to Offer Update on Keyzilen Program

October 10, 2016 4:14 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide an update on the KeyzilenTM development program tomorrow, Tuesday, October 11, 2016. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the program update for KeyzilenTM, which is in Phase 3 development for the treatment of acute inner ear tinnitus.

To participate in this conference call, dial 1-855-217-7942 (USA) or +1-646-254-3376 (International), and enter passcode 2939516. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at A replay will be available approximately two hours following the live call.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Momentum Movers

Add Your Comment